Lisata Therapeutics, Inc. · NASDAQ:LSTA

Lisata Therapeutics — Q2 2025 Earnings Presentation

71 slides from Lisata Therapeutics's earnings presentation, Aug 7, 2025

Slide 2: Forward-looking statements advisory
Disclosure Forward-looking statements advisory This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historica
Slide 3: Lisata at a Glance
Lisata at a Glance Company Overview 3
Slide 4: Lisata Therapeutics Overview and Mission
Company Overview Lisata Therapeutics (Nasdaq: LSTA) OVERVIEW MISSION Clinical-stage therapeutics To safely enhance the treatment company rapidly developing a benefits of existing and emerging novel solid tumor targeting therapies for solid tumors and similar and penetration technology diseases utili
Slide 5: Lisata Therapeutics: Key attributes
Company Overview Lisata Therapeutics (Nasdaq: LSTA): Key attributes Seasoned Platform technology management with Proprietary field- Multiple product and validated by existing successful leading technology business milestones partnerships with international drug with global IP projected over the pote
Slide 6: Seasoned leadership with proven history of drug approvals worldwide
Company Overview Seasoned leadership with proven history of drug approvals worldwide David J. Mazzo, PhD Kristen K. Buck, MD President and Chief Executive Officer, Member of the Board of Directors Executive Vice President of R&D and Chief Medical Officer With >40 years of experience, Dr. Mazzo is a
Slide 7: Therapeutic Focus and Rationale
Therapeutic Focus and Rationale 7
Slide 8: Improved solid tumor treatment remains a vital, growing global need
Therapeutic Focus and Rationale Improved solid tumor treatment remains a vital, growing global need 2022 2050 Worldwide 20 million new cases with 10 35 million new cases with Cancer million deaths(1-2) 18.5 million deaths(3) Incidence Solid tumors account for more than 90% of all diagnosed cancers P
Slide 9: Current solid tumor treatments & patient outcomes are suboptimal
Therapeutic Focus and Rationale Current solid tumor treatments & patient outcomes are suboptimal Challenging tumor morphology and tumor microenvironment (TME) pose significant barriers to effective treatment and outcomes Tumor stroma acts as a physical barrier to anti-cancer agents An immunosuppress
Slide 10: Certepetide is designed to optimize solid tumor treatment
Therapeutic Focus and Rationale Certepetide is designed to optimize solid tumor treatment Certepetide: a proprietary internalizing RGD* (iRGD) cyclic peptide adjuvant with tumor specific targeting & penetration activity and tumor microenvironment modifying properties  Converts tumor stroma from a b
Slide 11: Certepetide possesses a strong Intellectual Property portfolio
Therapeutic Focus and Rationale Certepetide possesses a strong Intellectual Property portfolio  Eight families, comprising 11 granted patents (6 U.S.), 19 pending patents, one family in its PCT phase, and two in provisional status  Orphan Drug Designations bring 7 and 10 years of market exclusivit
Slide 12: Partnerships
Partnerships Noteworthy existing relationships and potential for many more 12
Slide 13: Existing partnerships support certepetide's promise and broad applicability
Partnerships Existing partnerships support certepetide’s promise and broad applicability R&D alliances contribute resources with minimal commercial interest in certepetide  Australasian Gastro-Intestinal Trials Group - Clinical Trialists Consortium (Australia & New Zealand)  WARPNINE - Foundation
Slide 14: Certepetide: Strong Scientific Foundation and Rationale
Certepetide Strong Scientific Foundation and Rationale 14
Slide 15: Certepetide mechanism of action: Unique, multi-step approach
Certepetide - Strong Scientific Foundation and Rationale Certepetide mechanism of action: Unique, multi-step approach 4 Resulting tumor penetration CendR pathway actuation triggers encapsulation 1 Integrin binding 2 Proteolytic cleavage 3 Neuropilin-1 binding of circulating co-administered anti-canc
Slide 16: Certepetide/iRGD selectively promotes intratumoral penetration
Certepetide - Strong Scientific Foundation and Rationale Certepetide/iRGD selectively promotes intratumoral penetration Whole body imaging of mice with pancreatic ductal adenocarcinoma (arrow) dosed with Fluorescent Quantum When co-administered with iRGD, nab- Dots (FQDs) with and without certepetid
Slide 17: Broad applicability & activity of certepetide/iRGD consistently demonstrated
Certepetide - Strong Scientific Foundation and Rationale Broad applicability & activity of certepetide/iRGD consistently demonstrated Sampling of >370 scientific publications showing improved survival Lung cancer + gemcitabine Breast cancer + nanoparticle nab-paclitaxel Breast cancer + Herceptin® Su
Slide 18: Certepetide/iRGD consistently improves immunotherapy efficacy in preclinical models
Certepetide - Strong Scientific Foundation Certepetide/iRGD consistently improves immunotherapy efficacy in multiple preclinical solid tumor models Solid Tumor Types Preclinical Observations  Intrahepatic cholangiocarcinoma  Improved overall survival  Pancreatic adenocarcinoma  Reduced tumor siz
Slide 19: Certepetide improves immunotherapy impact in cholangiocarcinoma
Certepetide - Strong Scientific Foundation and Rationale Certepetide improves immunotherapy impact in cholangiocarcinoma  Intrahepatic cholangiocarcinoma (ICC) has an immunosuppressive TME and a dense desmoplastic stroma with abnormal vasculature which together impede anti-cancer agent efficacy  L
Slide 20: iRGD enhances selective tumor penetration of trastuzumab
Certepetide - Strong Scientific Foundation and Rationale iRGD enhances selective tumor penetration of trastuzumab Mouse model injected with human BT474 breast tumors Trastuzumab is a monoclonal Ab that inhibits HER2 A B C Trastuzumab Trastuzumab + iRGD Tumor Liver Spleen Pancreas Heart Lung Kidney B
Slide 21: Certepetide development strategy: A two-pillar approach
Certepetide - Strong Scientific Foundation and Rationale Certepetide development strategy: A two-pillar approach Pursue rapid global registration in mPDAC, initially combined with Demonstrate certepetide effectiveness gemcitabine/nab-paclitaxel standard-of- when combined with a variety of other care
Slide 22: Positive Clinical Results Through Phase 2b
Positive Clinical Results Through Phase 2b 22
Slide 23: Certepetide improved survival in mPDAC in two Phase 1b/2a trials
Positive Clinical Results Through Phase 2b Certepetide improved survival in mPDAC in two independent, multicenter Phase 1b/2a trials 12.5 13.2 months 10.5 55% improvement Von Hoff 2013 Phase 3 11.1 Gemcitabine + Nab-paclitaxel(1) months Registration study establishing gemcitabine 8.5 + nab-paclitaxe
Slide 24: Certepetide demonstrated internal consistency in two Phase 1b/2a trials
Positive Clinical Results Through Phase 2b Certepetide demonstrated internal consistency in two Phase 1b/2a trials Von Hoff 2013 Phase 3 Gemcitabine + Nab-paclitaxel(1) Registration study establishing gemcitabine + 9.7 nab-paclitaxel as SoC in mPDAC 96% 91% mo CEND1-001 Australia 87% Gemcitabine + N
Slide 25: Remarkable evidence of certepetide activity in other solid tumors
Positive Clinical Results Through Phase 2b Remarkable evidence of certepetide activity in other solid tumors Certepetide potentiated a complete response in metastatic gastroesophageal adenocarcinoma (mGEAC)  53-year-old male with mGEAC with significant FDG-PET* scan June 2022 FDG-PET scan Sept. 202
Slide 26: ASCEND: Phase 2b study of certepetide in mPDAC
Positive Clinical Results Through Phase 2b ASCEND: Phase 2b study of certepetide in mPDAC Investigator initiated trial inherited through Lisata amended protocol to ensure trial data will acquisition of Cend Therapeutics support global registration strategy  Sponsor: Australasian Gastro-Intestinal T
Slide 27: ASCEND: Phase 2b study chronology
Positive Clinical Results Through Phase 2b ASCEND: Phase 2b study chronology Enrollment initiated Protocol amended Cohort A enrollment Cohort A initial Cohort B initial data in Cohort A to add Cohort B completed data presented at presented at ESMO-GI May 2022 1Q 2023 2Q 2023 ASCO-GI Jan 2025 July 20
Slide 28: ASCEND: Preliminary Cohort A Progression-Free Survival data
Positive Clinical Results Through Phase 2b ASCEND: Preliminary Cohort A Progression-Free Survival data Cohort A: Progression-Free Survival (PFS) Data Data cut-off 4 November 2024 Standard of Care Certepetide + SoC Cohort A ONE IV PUSH OF CERTEPETIDE + SoC median  Cohort A powered for 6-month PFS Mo
Slide 29: ASCEND: Preliminary Cohort A Overall Survival data
Positive Clinical Results Through Phase 2b ASCEND: Preliminary Cohort A Overall Survival data Cohort A: Overall Survival (OS) Data Data cut-off 4 November 2024 Standard of Care Certepetide + SoC Cohort A ONE IV PUSH OF CERTEPETIDE + SoC median  Cohort A not powered for OS  Data mature - 76% (72 de
Slide 30: ASCEND: Preliminary Cohort B Progression-Free Survival data
Positive Clinical Results Through Phase 2b ASCEND: Preliminary Cohort B Progression-Free Survival data Cohort B: Progression-Free Survival (PFS) Data Data cut-off 30 December 2024 Cohort B TWO IV PUSHES OF CERTEPETIDE 4 HOURS APART + SoC  Cohort B not powered for PFS  Data mature  Despite not bei
Slide 31: ASCEND: Preliminary Cohort B Overall Survival data
Positive Clinical Results Through Phase 2b ASCEND: Preliminary Cohort B Overall Survival data Cohort B: Overall Survival (OS) Data Data cut-off 30 December 2024 Cohort B TWO IV PUSHES OF CERTEPETIDE 4 HOURS APART + SoC  Cohort B not powered for OS  Data mature - 71% (45 deaths out of 63)  mOS fav
Slide 32: Cohort B Time to Treatment Failure and Duration of Treatment
Positive Clinical Results Through Phase 2b Cohort B Time to Treatment Failure (TTF) and Duration of Treatment Data cut-off 30 December 2024 Cohort B: Time To Treatment Failure and Treatment Duration Cohort B TWO IV PUSHES OF CERTEPETIDE 4 HOURS APART + SoC  TTF and Treatment duration favor certepet
Slide 33: ASCEND: Phase 2b study of certepetide in mPDAC in summary
Positive Clinical Results Through Phase 2b ASCEND: Phase 2 study of certepetide in mPDAC in summary Certepetide improves clinical outcomes in mPDAC with benign safety profile  mOS in Cohort A numerically favored certepetide as did ORR (4 Complete Responses in the certepetide + SoC group and 0 in th
Slide 34: Certepetide Clinical Data Summary to Date
Positive Clinical Results Through Phase 2b Certepetide improves clinical outcomes in mPDAC with benign safety profile Certepetide Clinical Data Summary to Date  Two Phase 1b/2a clinical trials (CEND1-001 in Australia and CEND1-201 in China) demonstrate that certepetide plus SoC chemotherapy improve
Slide 35: Positive Early Clinical Results in Combination with I/O
Positive Early Clinical Results in Combination with I/O 35
Slide 36: iLSTA: Phase 1b/2a trial in locally advanced PDAC with chemo & IO
Positive Early Clinical Results in Combination with I/O iLSTA: Phase 1b/2a trial in locally advanced PDAC with chemo & IO Phase 1b/2a proof-of-concept safety and early efficacy study of LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel, as first-line treatment in locally advanced
Slide 37: Preliminary Efficacy as of May 2025 – Best Overall Response Rate
Positive Early Clinical Results in Combination with I/O Preliminary Efficacy as of May 2025 – Best Overall Response Rate Cohort 3: Overall Response Rate 69% Disease Control Rate 100% Key: Cohort 1 Cohort 2 Cohort 3: 11/16 with PR Stable disease Partial response * Complete response Percent Change (%)
Slide 38: Attractive Commercial Opportunity
Attractive Commercial Opportunity 38
Slide 39: Certepetide can be used throughout the mPDAC treatment paradigm
Attractive Commercial Opportunity Certepetide can be used throughout the mPDAC treatment paradigm First-Line (1L) Second-Line (2L) Third-Line (3L) Good Patient FOLFIRINOX Gemcitabine Immunotherapy or Functional or + other treatment Status NALIRIFOX Nab-paclitaxel Patient CERTEPETIDE CERTEPETIDE CERT
Slide 40: Certepetide's broad value proposition beyond mPDAC
Attractive Commercial Opportunity Certepetide’s broad value proposition beyond mPDAC Breadth of Applicability Certepetide’s Commercial Prospects Oncologic applications:  Well-characterized, de-risked, in later stage development  Locally advanced PDAC - a population recognized as non-  Capital eff
Slide 41: Certepetide special regulatory designations and benefits
Attractive Commercial Opportunity Certepetide special regulatory designations and benefits FDA Rare Pediatric Disease FDA Fast Track Designation Orphan Drug Designations Designation • Pancreatic cancer (FDA) • Osteosarcoma (FDA) • Pancreatic cancer (FDA & EMA) • Malignant glioma (FDA)  Eligible for
Slide 42: Poised for Global Phase 3 Initiation
Poised for Global Phase 3 Initiation 42
Slide 43: Requisite clinical development steps completed in preparation for Phase 3 trial
Poised for Global Phase 3 Initiation Requisite clinical development steps completed in preparation for Phase 3 trial Full NDA-ready preclinical toxicology package  no DLTs observed Phase 1 dose ranging study in 1L mPDAC  No DLTs observed; safety profile consistent with co-administered SoC  Certep
Slide 44: Phase 3 study design agreed with FDA
Poised for Global Phase 3 Initiation Phase 3 study design agreed with FDA  Global Phase 3, open-label, randomized clinical trial evaluating the efficacy and safety of certepetide in combination with standard of care (gemcitabine and nab-paclitaxel) vs. standard of care alone in patients with 1L mPD
Slide 45: Certepetide Development Portfolio
Certepetide Development Portfolio 45
Slide 46: Certepetide capital efficient clinical development plan
Certepetide – Clinical / Regulatory Development Portfolio Certepetide capital efficient clinical development plan Current Phase Sponsor(s) Indication Description Phase 1 Phase 2 Phase 3  ASCEND: Phase 2b, placebo-controlled trial (N=158) Cohort A data available AGITG/Lisata First-line mPDAC  Gemci
Slide 47: Certepetide preclinical activities and results
Certepetide – Clinical / Regulatory Development Portfolio Certepetide preclinical activities and results Sponsor(s) Indication Objective and Description Results Assess the therapeutic effect of adding certepetide to bevacizumab (VEGF inhibitor) on the size and number of  Encouraging early signals s
Slide 48: Clinical Development Milestones
Clinical Development Milestones 48
Slide 49: A wealth of key certepetide clinical milestones
Clinical Development Milestones A wealth of key certepetide clinical milestones 1Q 2024 2Q 2024 3Q 2024 4Q 2024 1Q 2025 2Q 2025 3Q 2025 4Q 2025 1Q 2026 2Q 2026 FDA EOP2 Final Cohort A & B ASCEND [AUS, NZ] Cohort A data meeting Cohort B data PFS/OS data First-line mPDAC 1L CCA LPI 1L OS 2L OS data BO
Slide 50: Financial Summary
Financial Summary 50
Slide 51: Capital projected to fund all clinical programs to data
Financial Summary Capital projected to fund all clinical programs to data Cash & Investments Debt Projected Cash Runway into As of 6/30/2025 $22.0M $0 4Q 2026 Common Shares Outstanding (6/30/2025): 8.6 million shares Options Outstanding (6/30/2025): Exercise Price: $0.02 - $4.22 = 1,293,100 shares 1
Slide 52: Key factors supporting investment in Lisata Therapeutics
Strong Investment Rationale Key factors supporting investment in Lisata Therapeutics INTELLECTUAL PEOPLE MILESTONES CAPITAL PARTNERING PROPERTY Seasoned Platform Proprietary field- Multiple product $22.0 million management with technology leading technology and business cash*- no debt; successful va
Slide 53: Targeted Therapy Delivered
Targeted Therapy Delivered Investor Relations Contact: John D. Menditto VP, IR & Corporate Communications Tel: (908) 842-0084 | Email: jmenditto@lisata.com Nasdaq: LSTA | www.lisata.com © Lisata Therapeutics, Inc. 2025. All rights reserved.
Slide 54: Appendix
Appendix 54
Slide 55: Certepetide capital efficient clinical development plan
Appendix Certepetide capital efficient clinical development plan Development Partner(s) Indication and Stage of Strategic Rationale [Development Venue] Trial Product/Comparator Development Lisata/AGITG First-line mPDAC; Phase 2b Corroborate Phase 1b results in a placebo-controlled trial and [Austral
Slide 56: ASCEND: Phase 2b, blinded, randomized trial in mPDAC
Appendix ASCEND: Phase 2b, blinded, randomized trial in mPDAC  Australasian Gastro-Intestinal Trials Group (AGITG) in collaboration with the NHMRC Clinical Sponsor/Partner Trials Centre at the University of Sydney  Lisata funded (LSTA eligible for ~43% rebate on all qualified R&D expenses in AUS)
Slide 57: ASCEND Phase 2b trial design
Appendix ASCEND Phase 2b trial design ONE IV push of certepetide per INTERVENTION Arm (N=63) • Nab-paclitaxel 125 mg/m2 IV infusion Phase 2b randomized, double-blind SoC treatment • ONE IV push of Certepetide 3.2 mg/kg study in mPDAC testing gemcitabine + • Gemcitabine 1000 mg/m2 IV infusion nab-pac
Slide 58: Phase 1b/2a open-label trial in mPDAC in China (CEND1-201)
Appendix Phase 1b/2a open-label trial in mPDAC in China (CEND1-201) Sponsor/Partner  Qilu Pharmaceutical (funds all development in China)  Evaluate safety, pharmacokinetics and preliminary efficacy of certepetide added to SoC in Objective Chinese patients with mPDAC  Phase 1b/2a open-label study
Slide 59: Qilu Phase 1b/2a trial design
Appendix Qilu Phase 1b/2a trial design Phase 1b/2a study evaluating the safety, pharmacokinetics, and preliminary efficacy of certepetide for injection in Chinese patients with advanced metastatic pancreatic ductal adenocarcinoma Certepetide 1.6 mPDAC 7 Day Safety mg/kg + nab-pac* + Disease 1.6 mg/k
Slide 60: CENDIFOX: Phase 1b/2a open-label trial in PDAC and other cancers
Appendix CENDIFOX: Phase 1b/2a open-label trial in PDAC and other cancers  University of Kansas Medical Center (Investigator initiated trial in U.S.) Sponsor/Partner  KUCC funded; Lisata provides certepetide  Evaluate the safety and therapeutic effect of certepetide in combination with neoadjuvan
Slide 61: CENDIFOX Phase 1b/2a trial design
Appendix CENDIFOX Phase 1b/2a trial design Phase 1b/2a open-label trial of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers (CENDIFOX) COHORT 1 Resectable and borderline resectable PDAC Repeat FOLFIRINOX Tissue FOLFIRINOX Biopsy (± P
Slide 62: BOLSTER: Phase 2 blinded, randomized trial in cholangiocarcinoma
Appendix BOLSTER: Phase 2 blinded, randomized trial in cholangiocarcinoma Sponsor/Partner  Lisata (U.S.)  Evaluate the preliminary efficacy, safety and tolerability of certepetide in combination with Objective standards of care in subjects with first- and second-line cholangiocarcinoma  Phase 2 r
Slide 63: BOLSTER Phase 2a trial design
Appendix BOLSTER Phase 2a trial design Phase 2a, double-blind, placebo-controlled, multi-center, randomized study evaluating certepetide when added to standard of care (SoC) versus standard of care alone in subjects with first- and second-line cholangiocarcinoma Disease Confirm Certepetide + cisplat
Slide 64: Phase 2 double-blind, placebo-controlled trial in mPDAC in China
Appendix Phase 2 double-blind, placebo-controlled trial in mPDAC in China Sponsor/Partner  Qilu Pharmaceutical (funds all development in China)  Further evaluate safety and therapeutic efficacy of certepetide when added to SoC in Objective Chinese patients with locally advanced unresectable mPDAC
Slide 65: Qilu Phase 2b trial design
Appendix Qilu Phase 2b trial design Phase 2b, double-blind, placebo-controlled, randomized, multicenter study evaluating the safety and efficacy of certepetide when added to standard of care (nab-paclitaxel and gemcitabine) vs. standard of care alone and placebo in Chinese subjects with locally adva
Slide 66: iLSTA: Phase 1b/2a trial in locally advanced PDAC with chemo & IO
Appendix iLSTA: Phase 1b/2a trial in locally advanced PDAC with chemo & IO  WARPNINE, Inc. (registered charity in Australia) is funding trial Sponsor/Partner  Lisata providing study drug  Evaluate safety and therapeutic effect of LSTA1 in combination with IO & Chemo in locally Objective advanced
Slide 67: iLSTA Phase 1b/2a trial design
Appendix iLSTA Phase 1b/2a trial design Phase 1b/2a proof-of-concept safety and early efficacy study of LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel, as first-line treatment in locally advanced non-resectable pancreatic ductal adenocarcinoma Cohort 1 Gemcitabine + nab-paclita
Slide 68: Preliminary iLSTA trial results poster at 2025 ASCO-GI Symposium
Appendix Preliminary iLSTA trial results poster at 2025 ASCO-GI Symposium An abstract with a detailed summary of the poster presentation is also available on the ASCO GI website: https://meetings.asco.org/abstracts-presentations/241611 68
Slide 69: Updated preliminary iLSTA trial results poster at 2025 ESMO-GI
Appendix Updated preliminary iLSTA trial results poster at 2025 ESMO-GI 69
Slide 70: Phase 2a trial of certepetide with SoC in first-line GBM
Appendix Phase 2a trial of certepetide with SoC in first-line GBM  Tartu University Hospital (Investigator initiated trial in Estonia, Latvia and Lithuania) Sponsor/Partner  Lisata providing study drug and funding trial  Evaluate safety, tolerability, and therapeutic effect of certepetide in comb
Slide 71: GBM Phase 2a trial design
Appendix GBM Phase 2a trial design Phase 2a proof-of-concept double-blind, placebo-controlled, randomized, proof-of-concept study evaluating certepetide when added to standard of care (temozolomide) versus temozolomide and matching certepetide placebo in subjects with newly diagnosed GBM Safety Lead

Lisata Therapeutics — Q2 2025 Earnings Presentation on 6ix

Lisata Therapeutics — Q2 2025 Earnings Presentation

Slide 1: Targeted Therapy Delivered

Slide 2: Forward-looking statements advisory

Slide 3: Lisata at a Glance

Slide 4: Lisata Therapeutics Overview and Mission

Slide 5: Lisata Therapeutics: Key attributes

Slide 6: Seasoned leadership with proven history of drug approvals worldwide

Slide 7: Therapeutic Focus and Rationale

Slide 8: Improved solid tumor treatment remains a vital, growing global need

Slide 9: Current solid tumor treatments & patient outcomes are suboptimal

Slide 10: Certepetide is designed to optimize solid tumor treatment

Slide 11: Certepetide possesses a strong Intellectual Property portfolio

Slide 12: Partnerships

Slide 13: Existing partnerships support certepetide's promise and broad applicability

Slide 14: Certepetide: Strong Scientific Foundation and Rationale

Slide 15: Certepetide mechanism of action: Unique, multi-step approach

Slide 16: Certepetide/iRGD selectively promotes intratumoral penetration

Slide 17: Broad applicability & activity of certepetide/iRGD consistently demonstrated

Slide 18: Certepetide/iRGD consistently improves immunotherapy efficacy in preclinical models

Slide 19: Certepetide improves immunotherapy impact in cholangiocarcinoma

Slide 20: iRGD enhances selective tumor penetration of trastuzumab

Slide 21: Certepetide development strategy: A two-pillar approach

Slide 22: Positive Clinical Results Through Phase 2b

Slide 23: Certepetide improved survival in mPDAC in two Phase 1b/2a trials

Slide 24: Certepetide demonstrated internal consistency in two Phase 1b/2a trials

Slide 25: Remarkable evidence of certepetide activity in other solid tumors

Slide 26: ASCEND: Phase 2b study of certepetide in mPDAC

Slide 27: ASCEND: Phase 2b study chronology

Slide 28: ASCEND: Preliminary Cohort A Progression-Free Survival data

Slide 29: ASCEND: Preliminary Cohort A Overall Survival data

Slide 30: ASCEND: Preliminary Cohort B Progression-Free Survival data

Slide 31: ASCEND: Preliminary Cohort B Overall Survival data

Slide 32: Cohort B Time to Treatment Failure and Duration of Treatment

Slide 33: ASCEND: Phase 2b study of certepetide in mPDAC in summary

Slide 34: Certepetide Clinical Data Summary to Date

Slide 35: Positive Early Clinical Results in Combination with I/O

Slide 36: iLSTA: Phase 1b/2a trial in locally advanced PDAC with chemo & IO

Slide 37: Preliminary Efficacy as of May 2025 – Best Overall Response Rate

Slide 38: Attractive Commercial Opportunity

Slide 39: Certepetide can be used throughout the mPDAC treatment paradigm

Slide 40: Certepetide's broad value proposition beyond mPDAC

Slide 41: Certepetide special regulatory designations and benefits

Slide 42: Poised for Global Phase 3 Initiation

Slide 43: Requisite clinical development steps completed in preparation for Phase 3 trial

Slide 44: Phase 3 study design agreed with FDA

Slide 45: Certepetide Development Portfolio

Slide 46: Certepetide capital efficient clinical development plan

Slide 47: Certepetide preclinical activities and results

Slide 48: Clinical Development Milestones

Slide 49: A wealth of key certepetide clinical milestones

Slide 50: Financial Summary

Slide 51: Capital projected to fund all clinical programs to data

Slide 52: Key factors supporting investment in Lisata Therapeutics

Slide 53: Targeted Therapy Delivered

Slide 54: Appendix

Slide 55: Certepetide capital efficient clinical development plan

Slide 56: ASCEND: Phase 2b, blinded, randomized trial in mPDAC

Slide 57: ASCEND Phase 2b trial design

Slide 58: Phase 1b/2a open-label trial in mPDAC in China (CEND1-201)

Slide 59: Qilu Phase 1b/2a trial design

Slide 60: CENDIFOX: Phase 1b/2a open-label trial in PDAC and other cancers

Slide 61: CENDIFOX Phase 1b/2a trial design

Slide 62: BOLSTER: Phase 2 blinded, randomized trial in cholangiocarcinoma

Slide 63: BOLSTER Phase 2a trial design

Slide 64: Phase 2 double-blind, placebo-controlled trial in mPDAC in China

Slide 65: Qilu Phase 2b trial design

Slide 66: iLSTA: Phase 1b/2a trial in locally advanced PDAC with chemo & IO

Slide 67: iLSTA Phase 1b/2a trial design

Slide 68: Preliminary iLSTA trial results poster at 2025 ASCO-GI Symposium

Slide 69: Updated preliminary iLSTA trial results poster at 2025 ESMO-GI

Slide 70: Phase 2a trial of certepetide with SoC in first-line GBM

Slide 71: GBM Phase 2a trial design